These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 26102212)
21. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814 [TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022 [TBL] [Abstract][Full Text] [Related]
23. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476 [TBL] [Abstract][Full Text] [Related]
24. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743 [TBL] [Abstract][Full Text] [Related]
26. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886 [TBL] [Abstract][Full Text] [Related]
27. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK; Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532 [TBL] [Abstract][Full Text] [Related]
28. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910 [TBL] [Abstract][Full Text] [Related]
29. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325 [TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954 [TBL] [Abstract][Full Text] [Related]
31. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434 [TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705 [TBL] [Abstract][Full Text] [Related]
34. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572 [TBL] [Abstract][Full Text] [Related]
35. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532 [TBL] [Abstract][Full Text] [Related]
36. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364 [TBL] [Abstract][Full Text] [Related]
37. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605 [TBL] [Abstract][Full Text] [Related]
38. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345 [TBL] [Abstract][Full Text] [Related]
39. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111 [TBL] [Abstract][Full Text] [Related]
40. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]